Fmr LLC raised its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 6.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,238,917 shares of the biopharmaceutical company’s stock after acquiring an additional 295,553 shares during the quarter. Fmr LLC owned approximately 14.24% of MacroGenics worth $91,733,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of MacroGenics by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,391,322 shares of the biopharmaceutical company’s stock worth $24,362,000 after acquiring an additional 38,458 shares during the last quarter. State Street Corp boosted its stake in shares of MacroGenics by 20.0% during the 1st quarter. State Street Corp now owns 1,007,211 shares of the biopharmaceutical company’s stock worth $18,732,000 after acquiring an additional 167,720 shares during the last quarter. Northern Trust Corp boosted its stake in shares of MacroGenics by 8.5% during the 2nd quarter. Northern Trust Corp now owns 432,878 shares of the biopharmaceutical company’s stock worth $7,580,000 after acquiring an additional 33,914 shares during the last quarter. Teachers Advisors LLC boosted its stake in shares of MacroGenics by 2.2% during the 2nd quarter. Teachers Advisors LLC now owns 322,309 shares of the biopharmaceutical company’s stock worth $5,644,000 after acquiring an additional 6,859 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of MacroGenics by 4.4% during the 1st quarter. Geode Capital Management LLC now owns 260,670 shares of the biopharmaceutical company’s stock worth $4,847,000 after acquiring an additional 10,983 shares during the last quarter. Institutional investors and hedge funds own 84.47% of the company’s stock.

WARNING: This story was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/10/11/fmr-llc-has-91-73-million-stake-in-macrogenics-inc-mgnx.html.

A number of research analysts recently weighed in on MGNX shares. Stifel Nicolaus restated a “buy” rating and set a $34.00 target price on shares of MacroGenics in a research note on Tuesday, September 12th. SunTrust Banks, Inc. restated a “buy” rating and set a $26.00 target price on shares of MacroGenics in a research note on Friday, September 1st. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. ValuEngine cut shares of MacroGenics from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 3rd. Finally, BidaskClub upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company. MacroGenics has an average rating of “Hold” and an average price target of $30.30.

MacroGenics, Inc. (NASDAQ MGNX) opened at 17.53 on Wednesday. MacroGenics, Inc. has a 1-year low of $14.36 and a 1-year high of $31.85. The company’s 50 day moving average is $17.73 and its 200-day moving average is $18.18. The stock’s market cap is $645.07 million.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.05) by ($0.09). The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $15.82 million. MacroGenics had a negative net margin of 1,216.51% and a negative return on equity of 56.81%. The business’s revenue for the quarter was down 97.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.12 earnings per share. Equities research analysts forecast that MacroGenics, Inc. will post ($4.42) earnings per share for the current fiscal year.

MacroGenics Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNX).

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.